ECSP088878A - Proceso para la preparación de indazolil ureas que inhiben receptores de vanilloides del subtipo 1 (vr1) - Google Patents

Proceso para la preparación de indazolil ureas que inhiben receptores de vanilloides del subtipo 1 (vr1)

Info

Publication number
ECSP088878A
ECSP088878A EC2008008878A ECSP088878A ECSP088878A EC SP088878 A ECSP088878 A EC SP088878A EC 2008008878 A EC2008008878 A EC 2008008878A EC SP088878 A ECSP088878 A EC SP088878A EC SP088878 A ECSP088878 A EC SP088878A
Authority
EC
Ecuador
Prior art keywords
subtipo
indazolil
ureas
preparation
vanilloid receptors
Prior art date
Application number
EC2008008878A
Other languages
English (en)
Inventor
Kirill A Lukin
Hsu Margaret Chi-Ping
Dilinie P Fernando
Brian J Kotecki
Marvin R Leanna
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of ECSP088878A publication Critical patent/ECSP088878A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Un proceso de preparar indazolilureas que son útiles como antagonistas del receptor de vainilloides de subtipo 1 (VR1).
EC2008008878A 2006-04-14 2008-11-11 Proceso para la preparación de indazolil ureas que inhiben receptores de vanilloides del subtipo 1 (vr1) ECSP088878A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79209906P 2006-04-14 2006-04-14
PCT/US2007/066605 WO2007121339A2 (en) 2006-04-14 2007-04-13 Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (vr1) receptors

Publications (1)

Publication Number Publication Date
ECSP088878A true ECSP088878A (es) 2008-12-30

Family

ID=38610399

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008878A ECSP088878A (es) 2006-04-14 2008-11-11 Proceso para la preparación de indazolil ureas que inhiben receptores de vanilloides del subtipo 1 (vr1)

Country Status (20)

Country Link
US (2) US7847104B2 (es)
EP (1) EP2012779B1 (es)
JP (1) JP2009533474A (es)
KR (2) KR20110017464A (es)
CN (4) CN101466374B (es)
AU (1) AU2007238019B2 (es)
BR (1) BRPI0709963A2 (es)
CA (1) CA2647261A1 (es)
CR (1) CR10357A (es)
EC (1) ECSP088878A (es)
ES (1) ES2385404T3 (es)
MX (1) MX2008013205A (es)
MY (1) MY145334A (es)
NO (1) NO20084698L (es)
NZ (1) NZ571705A (es)
RU (1) RU2446161C2 (es)
TW (1) TW200815362A (es)
UA (1) UA94100C2 (es)
WO (1) WO2007121339A2 (es)
ZA (1) ZA200808596B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2214675B1 (en) * 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
CN102036969A (zh) * 2008-03-20 2011-04-27 雅培制药有限公司 制造作为trpv1拮抗剂的中枢神经系统药剂的方法
CN102070420B (zh) * 2011-01-04 2013-12-18 常州大学 一种2-溴-6-氟苯甲醛的制备方法
US20140275505A1 (en) * 2013-03-13 2014-09-18 Dow Agrosciences Llc Process for the preparation of certain triaryl rhamnose carbamates
MX2019000512A (es) 2016-07-12 2019-05-02 Bayer Cropscience Ag Compuestos biciclicos como plaguicidas.
CN106977535A (zh) * 2017-04-28 2017-07-25 大连联化化学有限公司 一种合成2‑氰基3‑氟苯硼酸工艺

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054833A (es) * 1963-08-09
DE2458965C3 (de) * 1974-12-13 1979-10-11 Bayer Ag, 5090 Leverkusen 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
DE69411176T2 (de) 1993-08-20 1998-11-12 Smithkline Beecham Plc Amide und harnstoffderivate als 5ht1d rezeptor antagonisten
MXPA04003954A (es) * 2001-10-26 2004-11-29 Aventis Pharma Inc Bencimidazoles.
JP2005533014A (ja) * 2002-04-26 2005-11-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 置換ピラジン誘導体
CN1826324B (zh) * 2003-05-22 2011-12-07 雅培制药有限公司 吲唑、苯并异*唑和苯并异噻唑激酶抑制剂
US7375126B2 (en) * 2003-06-12 2008-05-20 Abbott Laboratories Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
CA2530679A1 (en) * 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds for treating angiogenesis
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
WO2006020070A2 (en) * 2004-07-16 2006-02-23 Teva Pharmaceutical Industries, Ltd. Indanylamino uracils and their use as antioxidants and neuroprotectants
US20070021450A1 (en) * 2004-07-16 2007-01-25 Benjamin Sklarz Indanylamino uracils and their use as antioxidants and neuroprotectants
WO2007021937A2 (en) * 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
US20070161645A1 (en) * 2005-11-02 2007-07-12 Targegen, Inc. Thiazole inhibitors targeting resistant kinase mutations
BRPI0619263A2 (pt) * 2005-11-30 2011-09-27 Hoffmann La Roche indóis de 3-amino-1-arilpropila e indóis aza-substituìdos, métodos para prepará-los, composição farmacêutica e uso dos referidos indóis

Also Published As

Publication number Publication date
KR20110017464A (ko) 2011-02-21
EP2012779B1 (en) 2012-05-16
CA2647261A1 (en) 2007-10-25
AU2007238019B2 (en) 2013-03-14
KR20090003335A (ko) 2009-01-09
CR10357A (es) 2008-12-11
HK1123725A1 (en) 2009-06-26
US7847104B2 (en) 2010-12-07
MX2008013205A (es) 2008-10-22
CN101466374A (zh) 2009-06-24
UA94100C2 (ru) 2011-04-11
TW200815362A (en) 2008-04-01
US20070244178A1 (en) 2007-10-18
CN101466374B (zh) 2012-03-21
WO2007121339A3 (en) 2008-10-02
US20110040102A1 (en) 2011-02-17
EP2012779A2 (en) 2009-01-14
BRPI0709963A2 (pt) 2011-08-02
WO2007121339A2 (en) 2007-10-25
RU2446161C2 (ru) 2012-03-27
RU2008144961A (ru) 2010-05-20
JP2009533474A (ja) 2009-09-17
ZA200808596B (en) 2010-03-31
NO20084698L (no) 2008-11-07
ES2385404T3 (es) 2012-07-24
CN102775350A (zh) 2012-11-14
EP2012779A4 (en) 2010-11-24
KR101118932B1 (ko) 2012-02-27
CN102321025A (zh) 2012-01-18
MY145334A (en) 2012-01-31
AU2007238019A1 (en) 2007-10-25
US8519186B2 (en) 2013-08-27
CN102140081A (zh) 2011-08-03
NZ571705A (en) 2012-03-30

Similar Documents

Publication Publication Date Title
ECSP088989A (es) (aza)ciclohexanos carboxilados nuevos como ligandos de receptores de dopamina d3
CR10872A (es) Compuestos agonistas y antagonistas del receptor de esfingosina-1-fosfato
UY32996A (es) Antagonistas del receptor crth2 basados en indol
CO2018004800A2 (es) Antagonistas del receptor muscarinico 4 y metodos de uso.
AR061727A1 (es) Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
UY32225A (es) Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2
UY32327A (es) Antagonistas de receptores de ácido lisofosfatídico
ECSP088878A (es) Proceso para la preparación de indazolil ureas que inhiben receptores de vanilloides del subtipo 1 (vr1)
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
UY35572A (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4)
UY31124A1 (es) Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842
ECSP11011433A (es) Fenilureas y fenilamidas sustituidas como ligandos del receptor de vanilloides
HN2008000646A (es) Antagonistas de los receptores 2 de dopamina de rapida disociacion
ECSP11011439A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
EA201000316A1 (ru) Производные изохинолинила и изоиндолинила в качестве антагонистов гистаминовых рецепторов 3 подтипа
CO6470826A2 (es) Moduladores de lxr
NI201300102A (es) Análogos del ácido epoxieicosatrienoicos y métodos de preparación y uso del mismo
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
ECSP099692A (es) Ligandos de receptor de vainilloide novedosos y su uso de los mismos para la produccion de sustancias farmaceuticas
CL2008003266A1 (es) Compuestos derivados de pirimidindiona y triazindiona sustituidas con cicloguanidina, utiles como antagonista del receptor de procineticina; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades gastrointestinales.
CR10540A (es) Derivados ciclopropil amina
ECSP13012495A (es) Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina
CR9923A (es) Compuestos triciclicos utiles como agonistas de receptores de oxitocina
CO6300937A2 (es) Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu
CR11828A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico